Jefferies Financial Group Inc. purchased a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 71,992 shares of the company’s stock, valued at approximately $907,000.
Several other hedge funds have also added to or reduced their stakes in the company. Global Retirement Partners LLC bought a new position in Amneal Pharmaceuticals in the fourth quarter valued at about $115,000. Covestor Ltd boosted its holdings in Amneal Pharmaceuticals by 4,883.4% in the fourth quarter. Covestor Ltd now owns 9,618 shares of the company’s stock valued at $121,000 after acquiring an additional 9,425 shares during the last quarter. Handelsbanken Fonder AB boosted its holdings in Amneal Pharmaceuticals by 38.2% in the fourth quarter. Handelsbanken Fonder AB now owns 53,900 shares of the company’s stock valued at $679,000 after acquiring an additional 14,900 shares during the last quarter. ProShare Advisors LLC lifted its stake in Amneal Pharmaceuticals by 12.1% in the fourth quarter. ProShare Advisors LLC now owns 41,381 shares of the company’s stock valued at $521,000 after buying an additional 4,461 shares during the period. Finally, HighTower Advisors LLC acquired a new position in Amneal Pharmaceuticals in the fourth quarter valued at about $1,121,000. Institutional investors own 31.82% of the company’s stock.
Wall Street Analyst Weigh In
AMRX has been the topic of several analyst reports. Barclays increased their target price on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Weiss Ratings lowered Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday. Truist Financial increased their target price on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. UBS Group initiated coverage on Amneal Pharmaceuticals in a research note on Friday, April 17th. They issued a “buy” rating and a $19.00 target price on the stock. Finally, Zacks Research lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Amneal Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $15.17.
Amneal Pharmaceuticals Price Performance
NASDAQ AMRX opened at $13.17 on Friday. The firm has a market cap of $4.20 billion, a P/E ratio of 34.66 and a beta of 1.32. The stock’s 50-day moving average is $12.62 and its 200-day moving average is $12.92. Amneal Pharmaceuticals, Inc. has a one year low of $7.07 and a one year high of $15.42.
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.27 EPS for the quarter. The company had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%. Equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current year.
Insider Activity at Amneal Pharmaceuticals
In other news, Director Deborah M. Autor sold 34,819 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the sale, the director owned 93,660 shares of the company’s stock, valued at $1,211,960.40. This trade represents a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 17.30% of the stock is currently owned by corporate insiders.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.
Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.
Featured Articles
- Five stocks we like better than Amneal Pharmaceuticals
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report).
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
